Platelet activation: a promoter for psoriasis and its comorbidity, cardiovascular disease

Abstract

Psoriasis is a chronic inflammatory skin disease with a prevalence of 0.14% to 1.99%. The underlying pathology is mainly driven by the abnormal immune responses including activation of Th1, Th17, Th22 cells and secretion of cytokines. Patients with psoriasis are more likely to develop cardiovascular disease (CVD) which has been well recognized as a comorbidity of psoriasis. As mediators of hemostasis and thromboinflammation, platelets play an important part in CVD. However, less is known about their pathophysiological contribution to psoriasis and psoriasis-associated CVD. A comprehensive understanding of the role of platelet activation in psoriasis might pave the path for more accurate prediction of cardiovascular (CV) risk and provide new strategies for psoriasis management, which alleviates the increased CV burden associated with psoriasis. Here we review the available evidence about the biomarkers and mechanisms of platelet activation in psoriasis and the role of platelet activation in intriguing the common comorbidity, CVD. We further discussed the implications and efficacy of antiplatelet therapies in the treatment of psoriasis and prevention of psoriasis-associated CVD.

Association between systemic immune-inflammation index and psoriasis: a population-based study

“…These biomarkers include platelet-derived microparticles (PDMPs) and mean platelet volume (MPV). Interestingly, a positive correlation has been observed between the levels of these biomarkers and PASI scores ( 63 ). The core pathogenesis of psoriasis involves aberrant function of multiple T-cell subsets, including regulatory T cells (Tregs), T helper (Th)1 cells, Th2 cells, Th17 cells, and Th22 cells, accompanied by aberrant release of associated cytokines, such as IFN-γ, tumor necrosis factor (TNF)-α, and members of the IL-23 and IL-17 families ( 45 ).…”

Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis

“…Psoriasis is a typical inflammatory skin disease ( 62 ). An underlying mechanism for our results may be related to inflammation and lipid metabolism, which has been reported in other inflammatory skin diseases ( 63 , 64 ).…”

Exploration of the biomarkers of comorbidity of psoriasis with inflammatory bowel disease and their association with immune infiltration

“…C‐Fos, a member of the Fos family, showed a correlation with Th1 and Th17 cell‐associated chemokines 28 . However, Th1, Th17 cells and secretion of cytokines can drive underlying pathology of psoriasis, and the imbalance of Th17 promotes IBD 29,30 . Recently, the effects of Fra‐1(Fos‐related antigen1), one of the clans of the FOS family in activator protein, are gradually revealed in psoriasis 31 .…”

“… 28 However, Th1, Th17 cells and secretion of cytokines can drive underlying pathology of psoriasis, and the imbalance of Th17 promotes IBD. 29 , 30 Recently, the effects of Fra‐1(Fos‐related antigen1), one of the clans of the FOS family in activator protein, are gradually revealed in psoriasis. 31 A significant increase in the proportion of Fos related antigen‑1‑positive intestinal mucosa epithelial cells in active IBD.…”